Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643660 | 0.74 | KMT2A (0.34) | POLBTHRB | |
| SCHEMBL4644186 | 0.74 | HSD17B10 (0.40) | GAAPOLBTHRB | |
| SCHEMBL4643685 | 0.72 | ERN1 (0.42) | — | |
| SCHEMBL4644487 | 0.72 | POLB (0.36) | GAAPOLBTHRB | |
| SCHEMBL6247098 | 0.72 | ZDHHC2 (0.48) | THRB | |
| SCHEMBL225748 | 0.71 | THRB (0.40) | THRB | |
| SCHEMBL4642186 | 0.71 | THRB (0.45) | GAATHRB | |
| SCHEMBL4643737 | 0.71 | MEN1 (0.44) | THRBESR1 | |
| SCHEMBL4645333 | 0.71 | THRB (0.45) | THRBESR1 | |
| SCHEMBL128030 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | claimed |
| US-7847119-B2 | Drug conjugates | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080139815-A1 | DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-12 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1718335-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | GAA 1638/4885POLB 1191/4885THRB 468/4885 |
| US-20080139815-A1 | DRUG CONJUGATES | RXRB, NR0B1, RXRA | GAA 1606/4885POLB 1155/4885THRB 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.